BR9711541A - Dihidrato d de olanzapina - Google Patents

Dihidrato d de olanzapina

Info

Publication number: BR9711541A
Authority: BR; Brazil
Prior art keywords: olanzapine dihydrate; olanzapine; dihydrate
Prior art date: 1996-09-23

Application number

BR9711541A

Other languages

English (en)

Inventor

Samuel Dean Larsen

John Richard Nicholson

Susan Marie Reutzel

Gregory Alan Stephenson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-18

Publication date

1999-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21832112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9711541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-09-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-08-24 Publication of BR9711541A publication Critical patent/BR9711541A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BR9711541A 1996-09-23 1997-09-18 Dihidrato d de olanzapina BR9711541A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2648696P	1996-09-23	1996-09-23
PCT/US1997/016586 WO1998011893A1 (en)	1996-09-23	1997-09-18	Olanzapine dihydrate d

Publications (1)

Publication Number	Publication Date
BR9711541A true BR9711541A (pt)	1999-08-24

Family

ID=21832112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9711541A BR9711541A (pt)	1996-09-23	1997-09-18	Dihidrato d de olanzapina

Country Status (34)

Country	Link
US (1)	US6251895B1 (pt)
EP (1)	EP0831097B1 (pt)
JP (1)	JP2001500878A (pt)
KR (1)	KR100516088B1 (pt)
CN (1)	CN1146567C (pt)
AR (1)	AR009801A1 (pt)
AT (1)	ATE221074T1 (pt)
AU (1)	AU720366B2 (pt)
BR (1)	BR9711541A (pt)
CA (1)	CA2266444C (pt)
CO (1)	CO4900057A1 (pt)
CZ (1)	CZ299247B6 (pt)
DE (1)	DE69714165T2 (pt)
DK (1)	DK0831097T3 (pt)
EA (1)	EA001881B1 (pt)
EG (1)	EG23815A (pt)
ES (1)	ES2180899T3 (pt)
HU (1)	HU226167B1 (pt)
ID (1)	ID21924A (pt)
IL (1)	IL128956A0 (pt)
MY (1)	MY125467A (pt)
NO (1)	NO323979B1 (pt)
NZ (1)	NZ334346A (pt)
PE (1)	PE110298A1 (pt)
PL (1)	PL194074B1 (pt)
PT (1)	PT831097E (pt)
RS (1)	RS49597B (pt)
SI (1)	SI0831097T1 (pt)
SV (1)	SV1997000079A (pt)
TR (1)	TR199900639T2 (pt)
TW (1)	TW518335B (pt)
UA (1)	UA56184C2 (pt)
WO (1)	WO1998011893A1 (pt)
ZA (1)	ZA978512B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
US6617321B2 (en)	1997-09-30	2003-09-09	Eli Lilly And Company	2-methyl-thieno-benzodiazepine formulation
CZ302367B6 (cs) *	1998-09-30	2011-04-13	Eli Lilly And Company	2-Methylthienobenzodiazepinový prípravek
US7022698B2 (en)	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
EP1246827B1 (en) *	1999-12-28	2005-04-13	Cipla Limited	New polymorphic forms of olanzapine
IL154688A0 (en) *	2000-08-31	2003-09-17	Reddys Lab Ltd Dr	Hydrates of olanzapine and processes for the preparation thereof
US6740753B2 (en)	2001-01-04	2004-05-25	Geneva Pharmaceuticals, Inc.	Olanzapine crystal modification
EP1440074A1 (en) *	2001-10-29	2004-07-28	Dr. Reddy's Laboratories Ltd.	Olanzapine dihydrate-ii a process for its preparation and use thereof
US7297789B2 (en)	2002-05-31	2007-11-20	Sandoz, Inc.	Process of preparation of olanzapine form I
SI21270A (sl)	2002-07-15	2004-02-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kristalne oblike olanzapina in postopki za njihovo pripravo
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7323459B2 (en) *	2002-12-24	2008-01-29	Teva Pharmaceutical Industries Ltd.	Crystal forms, methods for their preparation and method for preparation of olanzapine
US6861422B2 (en)	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2546200A1 (en) *	2003-11-18	2005-06-02	3M Innovative Properties Company	Olanzapine containing transdermal drug delivery compositions
ATE504588T1 (de)	2004-01-27	2011-04-15	Synthon Bv	Stabile salze von olanzapin
DE102004029784A1 (de)	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de)	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
EP1781666A1 (en) *	2004-07-14	2007-05-09	Shasun Chemicals and Drugs Limited	Improved process for making form i of olanzapine.
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en)	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de)	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7829700B2 (en)	2004-09-06	2010-11-09	Shasun Chemicals And Drugs Limited	Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
EP1797038B1 (en)	2004-09-29	2012-06-13	Bayer Pharma Aktiengesellschaft	Thermodynamically stable form of bay 43-9006 tosylate
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2526092T3 (es) *	2004-11-16	2015-01-05	Alkermes Pharma Ireland Limited	Formulaciones de olanzapina en nanopartículas inyectables
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP4940152B2 (ja)	2005-01-05	2012-05-30	イーライリリーアンドカンパニー	パモ酸オランザピン二水和物
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007067714A2 (en) *	2005-12-08	2007-06-14	The Mclean Hospital Corporation	Treatment of sequelae of psychiatric disorders
US7834176B2 (en) *	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US7439358B2 (en)	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
MX2008014024A (es)	2006-05-04	2008-11-14	Boehringer Ingelheim Int	Formas poliformas.
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US8039461B1 (en)	2006-11-10	2011-10-18	Pisgah Laboratories, Inc.	Physical states of a pharmaceutical drug substance
US7718649B1 (en)	2006-11-10	2010-05-18	Pisgah Labs, Inc.	Physical states of a pharmaceutical drug substance
EP3098223A1 (en)	2007-08-03	2016-11-30	Boehringer Ingelheim International GmbH	Crystalline form of a dihydropteridione derivative
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
NZ588311A (en) *	2008-07-24	2012-08-31	Handa Pharmaceuticals Llc	Stabilized atypical antipsychotic formulation to treat psychiatric conditions
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja)	2008-09-10	2012-01-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN107115530A (zh)	2009-11-27	2017-09-01	勃林格殷格翰国际有限公司	基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
CA2797310C (en)	2010-05-05	2020-03-31	Boehringer Ingelheim International Gmbh	Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EP3124041A1 (en)	2010-06-24	2017-02-01	Boehringer Ingelheim International GmbH	Diabetes therapy
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
HUE061596T2 (hu)	2011-07-15	2023-07-28	Boehringer Ingelheim Int	Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
EP4151218A1 (en)	2012-05-14	2023-03-22	Boehringer Ingelheim International GmbH	Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
JP2016027003A (ja) *	2012-11-20	2016-02-18	大蔵製薬株式会社	長期間安定なオランザピンの水性医薬製剤
JP2016525532A (ja)	2013-07-26	2016-08-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	骨髄異形成症候群の処置
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5302716A (en) *	1986-01-16	1994-04-12	Schering Corporation	Fused benzazepines
GB9009229D0 (en) *	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
CA2097016A1 (en) *	1992-05-29	1993-11-30	John Fairhurst	Pharmaceutical compounds
NZ289619A (en)	1994-06-28	1998-12-23	Grace W R & Co	Bag with patches, the patches having overhang regions which are adhered together
IL117612A0 (en) *	1995-03-24	1996-07-23	Lilly Co Eli	Granule formulation for olanzapine
US5631250A (en) *	1995-03-24	1997-05-20	Eli Lilly And Company	Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) *	1995-03-24	2008-11-10	Lilly Co Eli	Process for preparing olanzapine

1997
- 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
- 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
- 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active Expired - Fee Related
- 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
- 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
- 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
- 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
- 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
- 1997-09-18 CA CA002266444A patent/CA2266444C/en not_active Expired - Fee Related
- 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
- 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
- 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
- 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
- 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
- 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
- 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/en not_active Ceased
- 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
- 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
- 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
- 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
- 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
- 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
- 1997-09-22 EP EP97307379A patent/EP0831097B1/en not_active Expired - Lifetime
- 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
- 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
- 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
- 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
- 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
- 1997-09-23 EG EG98597A patent/EG23815A/xx active
- 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
- 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
1998
- 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
1999
- 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
EA199900325A1 (ru)	1999-08-26
CZ98999A3 (cs)	1999-08-11
UA56184C2 (uk)	2003-05-15
CN1146567C (zh)	2004-04-21
IL128956A0 (en)	2000-02-17
AU720366B2 (en)	2000-06-01
PL194074B1 (pl)	2007-04-30
TW518335B (en)	2003-01-21
YU15499A (sh)	2000-03-21
US6251895B1 (en)	2001-06-26
NO991339L (no)	1999-03-19
EP0831097A2 (en)	1998-03-25
AR009801A1 (es)	2000-05-03
KR20000048519A (ko)	2000-07-25
EA001881B1 (ru)	2001-10-22
DE69714165D1 (de)	2002-08-29
ES2180899T3 (es)	2003-02-16
RS49597B (sr)	2007-06-04
PE110298A1 (es)	1999-01-18
CN1234738A (zh)	1999-11-10
EG23815A (en)	2007-08-19
TR199900639T2 (xx)	1999-06-21
MY125467A (en)	2006-08-30
HU226167B1 (hu)	2008-05-28
CA2266444C (en)	2007-01-09
ATE221074T1 (de)	2002-08-15
JP2001500878A (ja)	2001-01-23
EP0831097B1 (en)	2002-07-24
EP0831097A3 (en)	1998-04-29
CZ299247B6 (cs)	2008-05-28
ID21924A (id)	1999-08-12
SI0831097T1 (en)	2003-02-28
HUP0000065A2 (hu)	2000-06-28
ZA978512B (en)	1999-03-23
WO1998011893A1 (en)	1998-03-26
DK0831097T3 (da)	2002-09-02
AU4424197A (en)	1998-04-14
PT831097E (pt)	2002-10-31
DE69714165T2 (de)	2003-01-23
CO4900057A1 (es)	2000-03-27
HK1009809A1 (en)	1999-06-11
SV1997000079A (es)	1999-01-13
KR100516088B1 (ko)	2005-09-22
NO323979B1 (no)	2007-07-30
NO991339D0 (no)	1999-03-19
PL332541A1 (en)	1999-09-13
HUP0000065A3 (en)	2000-11-28
NZ334346A (en)	2000-05-26
CA2266444A1 (en)	1998-03-26

Publication	Publication Date	Title
BR9711541A (pt)	1999-08-24	Dihidrato d de olanzapina
BR9711062A (pt)	1999-08-17	Tienopirimidinas
PT934320E (pt)	2003-07-31	Derivados de naftiridina
PT891332E (pt)	2004-07-30	Derivados de 6-fenilpiridil-2-amina
DE69936997D1 (de)	2007-10-11	Paletteneinrichtung
NO20002702D0 (no)	2000-05-26	Tienopyrimidiner
BR9709065A (pt)	1999-08-03	Derivados de alquilaminobenzotiazole e-benzoxazol
DK1334725T3 (da)	2007-06-11	Östroprogestativt antikonceptionsmiddel
ID17978A (id)	1998-02-12	Pembuatan 6-aminokapronitril
KR980000214U (ko)	1998-03-30	팬티
FI962420A0 (fi)	1996-06-11	Foerstaerkare med laogbrus
PT906279E (pt)	2003-02-28	Derivados de pirrol
ID16330A (id)	1997-09-18	Pembuatan asetaldehide
ID17636A (id)	1998-01-15	Pembuatan 6-aminokapronitril
ID17393A (id)	1997-12-24	Aril-piridazina terbaru
ID24110A (id)	2000-07-06	Pembuatan rutenium kompleks
ID20403A (id)	1998-12-10	PEMBUATAN α-TOKOFEROL
BR9706980A (pt)	1999-04-06	Derivados de isooxacefem
BR9708310A (pt)	1999-08-03	Derivados de 2-tioxotetrahidropirimidin-4-ona
KR960033232U (ko)	1996-11-19	반죽기
FI961814A0 (fi)	1996-04-29	Hjaelpstartapparat foer bil
PT9295T (pt)	1997-08-29	Autoclismo de dupla descarga
BR9704674A (pt)	1999-05-18	Derivados de n-benzilazólio
BR7600390U (pt)	1998-06-16	Tijolo
UA1360S (uk)	1997-02-28	Електронно-лазерний тир

Legal Events

Date	Code	Title	Description
2007-07-03	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-10-30	B12F	Other appeals [chapter 12.6 patent gazette]
2013-08-20	B07B	Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
2013-08-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 16A ANUIDADE
2014-02-18	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2225 DE 27/08/2013.